宣泰医药
(688247)
| 流通市值：45.74亿 | | | 总市值：45.74亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 191,160,204.92 | 94,546,671.06 | 446,568,888.08 | 331,464,771.67 |
| 营业总成本 | 173,790,467.08 | 82,432,049.12 | 394,329,144.83 | 276,521,555.79 |
| 其他经营收益 | | | | |
| 营业利润 | 29,949,498.06 | 14,924,782.56 | 55,318,824.23 | 69,568,355.21 |
| 利润总额 | 32,131,658.61 | 18,375,296.65 | 53,335,333.42 | 69,297,677.55 |
| 净利润 | 29,701,777.95 | 16,563,338.25 | 47,482,814.69 | 63,462,466.79 |
| 每股收益 | | | | |
| 其他综合收益 | -32,756.85 | -16,043.8 | -20,861.17 | -12,932.76 |
| 综合收益总额 | 29,669,021.1 | 16,547,294.45 | 47,461,953.52 | 63,449,534.03 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 977,919,135.72 | 955,309,544.35 | 934,873,260.06 | 973,235,675.23 |
| 非流动资产: | | | | |
| 非流动资产合计 | 497,064,549.14 | 498,760,415.03 | 503,226,123.37 | 483,087,588.34 |
| 资产总计 | 1,474,983,684.86 | 1,454,069,959.38 | 1,438,099,383.43 | 1,456,323,263.57 |
| 流动负债: | | | | |
| 流动负债合计 | 95,949,410.55 | 86,976,633.52 | 82,959,364.52 | 79,689,335.88 |
| 非流动负债: | | | | |
| 非流动负债合计 | 60,187,165.92 | 58,580,778.96 | 63,158,329.46 | 68,651,495.84 |
| 负债合计 | 156,136,576.47 | 145,557,412.48 | 146,117,693.98 | 148,340,831.72 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,318,847,108.39 | 1,308,512,546.9 | 1,291,981,689.45 | 1,307,982,431.85 |
| 股东权益合计 | 1,318,847,108.39 | 1,308,512,546.9 | 1,291,981,689.45 | 1,307,982,431.85 |
| 负债和股东权益合计 | 1,474,983,684.86 | 1,454,069,959.38 | 1,438,099,383.43 | 1,456,323,263.57 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 259,529,493.75 | 121,512,606.86 | 525,388,171.02 | 385,721,743.6 |
| 经营活动现金流出小计 | 174,481,612.14 | 81,335,248.17 | 430,062,312.71 | 308,280,964.53 |
| 经营活动产生的现金流量净额 | 85,047,881.61 | 40,177,358.69 | 95,325,858.31 | 77,440,779.07 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 406,857,527.71 | 166,248,724.65 | 1,971,636,920.89 | 1,505,141,803.21 |
| 投资活动现金流出小计 | 734,002,390.09 | 467,349,996.39 | 1,854,658,417.09 | 1,539,413,415.26 |
| 投资活动产生的现金流量净额 | -327,144,862.38 | -301,101,271.74 | 116,978,503.8 | -34,271,612.05 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | - | - |
| 筹资活动现金流出小计 | 6,284,854.38 | 16,840.8 | 27,906,438.83 | 18,442,389.52 |
| 筹资活动产生的现金流量净额 | -6,284,854.38 | -16,840.8 | -27,906,438.83 | -18,442,389.52 |
| 汇率变动对现金及现金等价物的影响 | -3,105,796.08 | -2,069,984.25 | -3,294,230.88 | -1,412,439.12 |
| 现金及现金等价物净增加额 | -251,487,631.23 | -263,010,738.1 | 181,103,692.4 | 23,314,338.38 |
| 期末现金及现金等价物余额 | 155,401,842.6 | 143,878,735.73 | 406,889,473.83 | 249,100,119.81 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -251,487,631.23 | - | 181,103,692.4 | - |